Ovarian serous carcinomas acquire cisplatin resistance and increased invasion through downregulation of the high-temperature-required protein A2 (HtrA2), following repeated treatment with cisplatin

High-temperature-required protein A2 as a predictive marker for response to chemotherapy and prognosis in patients with high-grade serous ovarian cancers

(2015) M Miyamoto et al.   BRITISH JOURNAL OF CANCER

Cancer statistics, 2014

(2014) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

p53-mediated activation of the mitochondrial protease HtrA2/Omi prevents cell invasion

(2014) Shota Yamauchi et al.   JOURNAL OF CELL BIOLOGY

The expression levels and prognostic value of high temperature required A2 (HtrA2) in NSCLC

(2014) Guoxin Mao et al.   PATHOLOGY RESEARCH AND PRACTICE

Clear cell histology as a poor prognostic factor for advanced epithelial ovarian cancer: a single institutional case series through central pathologic review

(2013) Morikazu Miyamoto et al.   Journal of Gynecologic Oncology

EMT transcription factors snail and slug directly contribute to cisplatin resistance in ovarian cancer

(2012) Alexandria M Haslehurst et al.   BMC CANCER

Repeated cisplatin treatment can lead to a multiresistant tumor cell population with stem cell features and sensitivity to 3-bromopyruvate

(2012) My Wintzell et al.   CANCER BIOLOGY & THERAPY

Changes in mRNA and protein levels of human HtrA1, HtrA2 and HtrA3 in ovarian cancer

(2008) Joanna Narkiewicz et al.   CLINICAL BIOCHEMISTRY